The growing prevalence of uterine fibroids, especially among women of reproductive age, is fueling the demand for treatment devices. This surge is fu ...

Efimosfermin is a long-acting engineered variant of FGF21 designed to have a prolonged half-life, the authors noted, and has ...

CHICAGO — Acute lymphoblastic leukemia (ALL) remains challenging to treat in older adult patients due to biological factors ...

GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it ...

Global Plasma Protease C1-Inhibitor Market is valued approximately USD 3752.3 million in 2023 and is anticipated to grow with a healthy growth rate of more than 17.72% over the forecast period ...

According to DelveInsight's analysis, the growth of the cancer pain market is expected to be mainly driven by increasing incidence and advances in disease mechanisms have yielded new diagnostic ...

The biopharma job market failed to turn around in May, but employers were still hiring, especially in Indiana and California, ...

Hemophilia A Market Trends The report provides a detailed analysis of the current hemophilia A marketed drugs and late-stage pipeline drugs ...

Each share of CureVac, a clinical-stage biotech company, will be exchanged for about $5.46 in BioNTech American depositary shares. Upon the deal’s closing, CureVac shareholders are expected to own ...

Amicus Therapeutics is growing steadily with Galafold and a promising Pompe therapy, targeting $1B revenue by 2028. See why ...